# Komal Jhaveri

Source: https://onco.cc/people/komal-jhaveri/  
OnCo record `komal-jhaveri` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads the next wave of endocrine therapy: oral SERDs like imlunestrant and the PI3K inhibitor inavolisib.

## Summary

Komal Jhaveri led EMBER-3, which showed the oral SERD imlunestrant plus abemaciclib improves progression-free survival in ER-positive advanced breast cancer after aromatase inhibitors, and was a lead investigator on INAVO120 (inavolisib for PIK3CA-mutant disease). She heads endocrine therapy research at MSKCC and runs early-phase trials of degraders and PI3K pathway agents.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: breast; endocrine; early-phase
- Role: Section Head, Endocrine Therapy Research, Memorial Sloan Kettering Cancer Center
- Specialisms: HR-positive breast cancer; Oral SERDs; PI3K/AKT pathway; Early drug development

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Jhaveri%20K%5BAuthor%5D%20breast%20SERD

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- technologies: [Endocrine therapy (SERMs, AIs, SERDs)](https://onco.cc/technologies/endocrine-therapy/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- targets: [Estrogen receptor (ERα)](https://onco.cc/targets/estrogen-receptor/), [PIK3CA / PI3K-alpha](https://onco.cc/targets/pik3ca/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Inavolisib](https://onco.cc/drugs/inavolisib/), [Palbociclib](https://onco.cc/drugs/palbociclib/)
- institutions: [Memorial Sloan Kettering Cancer Center](https://onco.cc/institutions/mskcc/)
- trials: [EMBER-3](https://onco.cc/trials/ember-3/), [INAVO120](https://onco.cc/trials/inavo120/)

---
JSON: https://onco.cc/api/v1/entities/komal-jhaveri.json